Oklahoma 2024 2024 Regular Session

Oklahoma Senate Bill SB1955 Comm Sub / Bill

Filed 02/13/2024

                     
 
Req. No. 3481 	Page 1  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
STATE OF OKLAHOMA 
 
2nd Session of the 59th Legislature (2024) 
 
COMMITTEE SUBSTITUTE 
FOR 
SENATE BILL 1955 	By: Standridge 
 
 
 
 
 
COMMITTEE SUBSTITUTE 
 
An Act relating to the Patient’s Right to Pharmacy 
Choice Act; defining terms; authorizing cause of 
action for certain violations; authorizing award of 
certain costs and fees; requiring award of certain 
damages upon specified sho wing by plaintiff; 
authorizing joinder of certain actions; providing for 
division of certain damage award; requiring certain 
evidence; authorizing discovery of specified 
information; authorizing intervention of Attorney 
General; providing for codification; and declaring an 
emergency. 
 
 
 
 
 
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 
SECTION 1.     NEW LAW     A new section of law to be codified 
in the Oklahoma Statutes as Section 6696.2 of Title 36, unless there 
is created a duplication in numbering, reads as follows: 
A.  As used in this act: 
1.  “Closely aligned pharmacy provider” means a pharmacy 
provider wholly or partially owned by : 
a. the pharmacy benefits manager (PBM), 
b. an entity that owns any portion of the PBM,   
 
Req. No. 3481 	Page 2  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
c. an entity owned wholly or partially by the PBM, or 
d. an entity closely aligned with the PBM which would be 
established by any other working relationship between 
the PBM and the pharmacy provider which would be 
construed as being beneficial to the PBM ; 
2.  “Damages” includes, but is not limited to, the difference in 
reimbursement between the plaintiff or plaintif fs and the highest 
total reimbursement, including drug pricing and any associated 
reimbursed costs, of a closely aligned ph armacy provider or any 
pharmacy provider that would be considered in competition with the 
plaintiff or plaintiffs provid ing pharmacy services to the PB M; 
3.  “Drug pricing” includes but is not limited to drug costs, 
rebates, incentives, discounts, kickbacks, profits, spread pricing, 
fees, and other pricing information that would cause a disparit y 
between reimbursement for the plaintiff or plaintiffs and other 
contracted pharmacy providers of the PBM ; 
4.  “Payment history” includes but is not limited to direct 
payments, rebates, discounts, kickbacks, credits , or any other form 
of benefit to the payee; and 
5.  “Pharmacy contract” means any contract between a PBM and a 
pharmacy provider. 
B.  1.  A licensed pharmacy or pharmacist located in this state 
who is aggrieved by a violation of the Patient’s Right to Pharmacy 
Choice Act, Section 6959 et seq. o f Title 36 of the Oklahoma   
 
Req. No. 3481 	Page 3  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
Statutes, related to pricing models or reimbursement r ates by a 
pharmacy benefits manager (PBM) or the entity for which the PBM 
performs pharmacy benefits management shall have a cause of action 
against the PBM or entity to recover damages attributable to such 
violation. In addition to actual damages, a court may award c ourt 
costs and reasonable attorney fees. 
2.  If a plaintiff shows that the disparity in reimbursement 
between the amount the PBM reimburses the plaintiff and the amount 
the PBM reimburses either a closely aligned pharmacy provider or any 
pharmacy provider that would be considered in competition with the 
plaintiff is financially harmful to the plaintiff while beneficial 
to the other provider, then such damage will be considered 
unnecessarily harmful to the plaintiff and the court shall award 
damages to the plaintiff in an amount needed to cover the financial, 
personal, and business harm that resulted from such unn ecessary 
financial harm and an amount needed to bring the plaintiff to the 
financial position tha t would have occurred if such unnecessary 
financial harm was not inflicted. 
3.  If more than one licensed pharmacy or phar macist has similar 
damages from the same PBM , such pharmacies or pharmacists may join 
their cause of action and any damage award shall be divided among 
the aggrieved parties according to the proportion of damages each 
party sustained.   
 
Req. No. 3481 	Page 4  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
C. A licensed pharmacy or pharmacis t, or more than one of 
either or both, filing an action pursuant to subsection B of this 
section shall be required to : 
1.  Present evidence of a consistent reimbursement rate that is 
less than the combined total of the cost of medication and the 
average cost of dispensing the medication as recognized in t he 
industry.  Each plaintiff must show a minimum of twelve (12) such 
instances in a ninety-day period to sustain a claim for damages 
under this section; or 
2.  Present evidence that a PBM initiated an audit against th e 
pharmacy or pharmacies in violation of the Pharmacy Audit Integr ity 
Act. 
D.  In an action filed pursuant to this section, the plaintiff 
or plaintiffs shall have rights of discovery in all relevant areas 
to determine the existenc e of unfair, anti-competitive, or 
monopolistic actions on behalf of the PBM. Such discovery may 
include but not be limited to : 
1.  Payment history and pharmacy contracts for similar pharmacy 
services to any closely aligned pharmacy provider or any pharmacy 
provider that would be considered in compe tition with the plaintiff 
or plaintiffs; 
2.  Communications related to the contract of the plaintiff or 
plaintiffs;   
 
Req. No. 3481 	Page 5  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
3.  Drug pricing or communications about drug pricing related to 
the plaintiff or plaintiffs, any closely aligned pharmacy provider, 
or contracted pharmacy providers of the PBM that would be considered 
competitors of the plaintiff or plaintiffs; or 
4.  Any information or communication related to the disparity i n 
reimbursement between the plaintiff or plaintiffs and any contracted 
pharmacy provider of the PBM when such information or communication 
would show anti-competitive or unfair business pract ices on the part 
of the PBM. 
E.  In addition to the oversight and investigative authority 
granted under the Patient’s Right to Pharmacy Choice Act, the 
Attorney General may intervene in any action filed pursuant to 
subsection B of this section. 
SECTION 2.  It being immediately necessary for the preservat ion 
of the public peace, health or safety, an emergency is hereby 
declared to exist, by reason whereof this act shall take effect and 
be in full force from and after its passage and approval. 
 
59-2-3481 RD 2/13/2024 3:09:14 PM